Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Remaining Weighted Average Amortization Period Intangible Asset, Finite-Lived, Remaining Amortization Period Schedule of components of intangible assets Intangible Asset and Goodwill [Table Text Block] Trading Arrangement: Trading Arrangement [Axis] Maximum Maximum [Member] Statistical Measurement [Domain] Statistical Measurement [Domain] Title of 12(b) Security Title of 12(b) Security Net income available to common shareholders, Diluted Net Income (Loss) Available to Common Stockholders, Diluted Document Fiscal Year Focus Document Fiscal Year Focus Revenue, remaining performance obligation, development milestones satisfied over time Revenue, Remaining Performance Obligation, Development Milestones Satisfied Over Time Revenue, Remaining Performance Obligation, Development Milestones Satisfied Over Time Maximum percentage of conversion price Percentage of Conversion Price Percentage of conversion price. Adjustment to Compensation, Amount Adjustment to Compensation Amount Non-option Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Customer [Axis] Customer [Axis] Segment Reporting [Abstract] Segment Reporting [Abstract] Common Stock, $0.0001 par value, 66,000,000 shares authorized; 23,853,338 shares issued and 22,961,423 shares outstanding at June 30, 2026; 23,112,577 shares issued and 22,491,281 shares outstanding at December 31, 2025 Common Stock, Value, Issued Accrued compensation and related expenses Employee-related Liabilities, Current Schedule of carrying value of the current and non-current components of the term loan Schedule of Long-Term Debt Instruments [Table Text Block] Performance period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period Line of Credit Line of Credit [Member] Restatement Determination Date Restatement Determination Date Derivative Instrument [Axis] Derivative Instrument [Axis] Issuance of Restricted Stock Units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Debt instrument, convertible, conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Amendment flag Amendment Flag Current Liabilities Liabilities, Current [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Royalty income, nonoperating Royalty Income, Nonoperating Renee Tannenbaum [Member] Renee Tannenbaum Current borrowing on debt Long-term Debt, Gross, Current Current portion before unamortized (discount) premium and debt issuance costs, of long-term debt. PIPE Shares PIPE Shares [Member] Information related to the Private Investment in Public Equity ("PIPE Investment"). Line of credit facility, effective rate Line of Credit Facility, Cash Interest Rate at Period End Line of Credit Facility, Cash Interest Rate at Period End Other comprehensive loss, net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Collaborative arrangement royalty payable on net revenue revenue threshold Collaborative Arrangement, Royalty Payable on Revenue, Threshold Collaborative Arrangement, Royalty Payable on Revenue, Threshold 2026 Milestone Revenue Payment 2026 Milestone Revenue Payment [Member] 2026 Milestone Revenue Payment Acquired ANDAs intangible assets Acquired ANDAs Intangible Assets [Member] Acquired ANDAs Intangible Assets RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Debt instrument convertible minimum aggregate principal outstanding Debt Instrument, Convertible, Minimum Aggregate Principal Amount Outstanding Debt Instrument, Convertible, Minimum Aggregate Principal Amount Outstanding Entity Address, State or Province Entity Address, State or Province Grants of stock options (in shares) Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent PEO Total Compensation Amount PEO Total Compensation Amount Business combination, milestone payment multiplier Contingent Consideration, Milestone Payment, Multiplier Contingent Consideration, Milestone Payment, Multiplier Common Stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Intangible assets, net Intangible Asset, Excluding Goodwill, after Accumulated Amortization Outstanding/ Unvested at the beginning of the period (in shares) Outstanding/ Unvested at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Convertible notes, net Convertible Notes Payable, Net , Noncurrent Convertible Notes Payable, Net , Noncurrent Basic Weighted-Average Shares Outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Total payments Related Party Transaction, Purchases from Related Party Schedule of related party transactions Schedule of Related Party Transactions [Table Text Block] Summary of stock option and restricted stock activity Share-Based Payment Arrangement, Activity [Table Text Block] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Number of annual installments Number of Annual Installments Number of Annual Installments SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Number of reporting units Number of Reportable Segments Total Current Liabilities Liabilities, Current CG Oncology CG Oncology [Member] CG Oncology Customer relationships Customer Relationships [Member] Concentration Risk [Table] Concentration Risk [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] Entity Address, City or Town Entity Address, City or Town Granted (in shares) Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Generics and Other total net revenues Total Sales of Generics and Other [Member] Total Sales of Generics and Other Share-based Compensation Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] 2024 Credit Agreement 2024 Credit Agreement [Member] 2024 Credit Agreement Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Title of Individual [Domain] Title and Position [Domain] Document Information Document Information [Line Items] Class C Special Stock Class C Special Stock [Member] Class C Special Stock Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Vested (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Class of Stock [Axis] Class of Stock [Axis] Threshold number of trading days Threshold Number of Trading Days Threshold number of trading days. Total Intangible Assets, net Intangible Asset, Finite-Lived, after Accumulated Amortization Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Debt issuance costs, gross Debt Issuance Costs, Gross Payments for royalties Payments for Royalties Line of credit facility, interest rate at period end Line of Credit Facility, Interest Rate at Period End Net income available to common shareholders, Basic Net Income (Loss) Available to Common Stockholders, Basic Revenue from Contract with Customer Benchmark Revenue from Contract with Customer Benchmark [Member] Accumulated Amortization Intangible Asset, Finite-Lived, Accumulated Amortization Level 2 Fair Value, Inputs, Level 2 [Member] Other (expense) income, net Nonoperating Income (Expense) [Abstract] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Accrued government rebates Increase Decrease, Accrued Government Rebates The increase (decrease) during the reporting period in liabilities related to government rebates. Total other comprehensive loss, net of tax Other Comprehensive Loss Other Comprehensive Income (Loss), Net of Tax Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Current debt, net Current debt, net Long-Term Debt, Current Maturities Allowance SEC Schedule, 12-09, Valuation Allowances, Amount SEC Schedule, 12-09, Valuation Allowances, Amount Dividends on Series A Convertible Preferred Stock Dividends, Preferred Stock Issuance of Restricted Stock Awards (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Concentration Risk Type [Axis] Concentration Risk Type [Axis] Loss on interest rate swap Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Schedule of Long-Term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Property and equipment purchased and included in accounts payable Capital Expenditures Incurred but Not yet Paid Schedule of financial information by reportable segments Segment Reporting [Table Text Block] Officer Officer [Member] Amortization of deferred financing costs Amortization of deferred financing costs Amortization of Debt Issuance Costs Use of Estimates Use of Estimates, Policy [Policy Text Block] Related Party [Axis] Related and Nonrelated Parties [Axis] Contingent Value Rights Agreement Contingent Value Rights Agreement [Member] Contingent Value Rights Agreement Up-front payment Collaborative Arrangement, Up-front Payment Collaborative Arrangement, Up-front Payment Interest rate swap Interest Rate Derivative Assets, at Fair Value Schedule of changes in contingent consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Total Long-Term Debt Generics and Other Generics and Other [Member] Generics and Other Temporary stock issued (in dollars per share) Temporary Equity, Redemption Price Per Share SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Document Period End Date Document Period End Date Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Net Cash and Cash Equivalents Used in Investing Activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Preferred Stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Aggregate principal amount Debt Instrument, Face Amount Basic Earnings Per Share, Basic [Abstract] STOCKHOLDERS' EQUITY Equity [Text Block] Balance (in shares) Balance (in shares) Convertible preferred stock outstanding (in shares) Temporary Equity, Shares Outstanding Security Exchange Name Security Exchange Name Treasury stock, 891,915 shares of common stock, at cost, at June 30, 2026 and 621,296 shares of common stock, at cost, at December 31, 2025 Treasury stock value Treasury Stock, Common, Value Debt effective interest rate (as a percent) Debt Instrument, Interest Rate, Effective Percentage Debt instrument accordion feature settlement period Debt Instrument, Accordion Feature, Settlement Period Debt Instrument, Accordion Feature, Settlement Period Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Brand royalties and other revenues Sales of Established Brand Royalties and Other Revenues [Member] Sales of Established Brand Royalties and Other Revenues Accumulated other comprehensive (loss) income, net of tax Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Shell Company Entity Shell Company Consolidation Items [Domain] Consolidation Items [Domain] Change in fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] EARNINGS PER SHARE Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Earnings Per Share [Abstract] Earnings Per Share [Abstract] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Royalty payments to be paid Royalty Payments to be Paid Royalty Payments to be Paid Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Total Liabilities Liabilities Trading Symbol Trading Symbol Discount rate Measurement Input, Discount Rate [Member] Schedule of components of total interest expense related to the notes and term loan Interest Income and Interest Expense Disclosure [Table Text Block] Acquisition of property and equipment, net Payments to Acquire Property, Plant, and Equipment Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Basic Weighted Average Number of Shares Outstanding, Basic [Abstract] Company Selected Measure Name Company Selected Measure Name Sale of Stock [Domain] Sale of Stock [Domain] Debt Instrument, Convertible Terms Of Conversion [Axis] Debt Instrument, Convertible Terms Of Conversion [Axis] Debt Instrument, Convertible Terms Of Conversion Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Diluted Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract] Non-cash interest Amortization of Debt Issuance Costs and Discounts Reclassification, Type [Axis] Reclassification, Type [Axis] The Credit Facility The Credit Facility [Member] The Credit Facility Diluted Earnings Per Share, Diluted [Abstract] Concentration Risk [Line Items] Concentration Risk [Line Items] Class C Special Stock, $0.0001 par value, 781,281 shares authorized; 10,864 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively Class C Special Stock Value Aggregate par or stated value of issued nonredeemable Class C Special stock (or common stock redeemable solely at the option of the issuer). Long-term debt, gross Long-Term Debt, Gross Investment in equity securities Equity Securities, FV-NI, Cost Commitment fee (as a percent) Line of Credit Facility, Commitment Fee Percentage Convertible Senior Notes due 2029 Convertible Senior Notes due 2029 [Member] Convertible Senior Notes due 2029 Credit Facility [Domain] Credit Facility [Domain] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Related Party Transactions [Abstract] Related Party Transactions [Abstract] Cash Flows From Operating Activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Novitium Novitium [Member] Novitium SThree SThree [Member] SThree Compensation Amount Outstanding Recovery Compensation Amount Individual: Individual [Axis] Diluted Weighted-Average Shares Outstanding (in shares) Diluted Weighted-Average Shares Outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Entity Emerging Growth Company Entity Emerging Growth Company Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Eye Point Agreements Member Eye Point Agreements Member [Member] Eye Point Agreements Member Underlying Security Market Price Change Underlying Security Market Price Change, Percent Deferred taxes Deferred Income Taxes and Tax Credits Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Prompt Payment Discounts Prompt Payment Discounts Reserves For Cash Discount Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Discount from market price (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date Award Timing Predetermined Award Timing Predetermined [Flag] Restricted cash Restricted Cash, Current Treasury Stock Treasury Stock, Common [Member] Intangible Asset, Goodwill and Other [Abstract] Intangible Asset, Goodwill and Other [Abstract] Cortrophin Gel Sales of Cortrophin Gel [Member] Sales of Cortrophin Gel Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Stock-based Compensation Expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Level 1 Fair Value, Inputs, Level 1 [Member] Generic pharmaceutical products Sales of Generic Pharmaceutical Products [Member] Sales of Generic Pharmaceutical Products Schedule of customer concentration Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Effective income tax rate (as a percent) Effective Income Tax Rate Reconciliation, Percent Contingent consideration fair value adjustment Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Cash Flow Cash flow impact of amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. Intangible Asset, Indefinite-Lived, Class [Domain] Intangible Asset, Indefinite-Lived, Class [Domain] Rare Disease and Brands total net revenues Total Sales Of Rare Disease and Brands [Member] Total Sales Of Rare Disease and Brands Esjay Esjay [Member] Represents the information pertaining to Esjay Pharma LLC. Debt instrument, convertible, conversion ratio Debt Instrument, Convertible, Conversion Ratio Dilutive effect of convertible senior notes, performance stock units, common stock options, and ESPP (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Collaborative arrangement, percentage of net profit generated by sales, quarterly payment due, accrued Collaborative Arrangement, Percentage of Net Profit Generated by Sales, Quarterly Payment Due, Accrued Collaborative Arrangement, Percentage of Net Profit Generated by Sales, Quarterly Payment Due, Accrued Employees and Consultants Employees and Consultants [Member] Information related to employees and consultants. Inventory, Current [Table] Inventory, Current [Table] All Executive Categories All Executive Categories [Member] Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Accrued Government Rebates Accrued Government Rebates [Member] Accrued Government Rebates Four Customers Three Customers [Member] Three Customers Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Repayments of long-term lines of credit Repayments of Long-Term Lines of Credit Preferred Stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Plan Name [Domain] Plan Name [Domain] Number of pharmaceutical manufacturing facilities Number of Pharmaceutical Manufacturing Facilities Number of Pharmaceutical Manufacturing Facilities Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract] Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Preferred stock, convertible, conversion price (in dollars per share) Preferred Stock, Convertible, Conversion Price Deferred financing costs Debt Issuance Costs, Current, Net Unapproved Products Unapproved Products Unapproved Products Schedule of earnings per share, basic and diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] SEGMENT REPORTING Segment Reporting [Text Block] Royalty percentage Loss Contingency, Damages Sought, Royalty Percentage Loss Contingency, Damages Sought, Royalty Percentage Minimum Minimum [Member] Reclassification, Type [Domain] Reclassification, Type [Domain] Expiration Date Trading Arrangement Expiration Date Cost of Goods and Service Benchmark Cost of Goods and Service Benchmark [Member] Schedule of disaggregation of revenue and revenue recognized Disaggregation of Revenue [Table Text Block] Customer 4 Customer four [Member] Customer four Beginning balance, permanent and temporary equity Ending balance, permanent and temporary equity Stockholders' Equity Attributable to Parent and Temporary Equity Total of all stockholders' equity (deficit) items attributable to the parent and temporary equity. Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Income Statement Location [Axis] Location, Statement of Income, Balance [Axis] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Money market fund Money Market Fund Cash and Cash Equivalents, Fair Value Disclosure Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Returned goods reserve Returned Goods Reserve Represents the reserve for goods returned. Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Common Stock, shares authorized (in shares) Common Stock, Shares Authorized Basic and Diluted Income Per Share: Earnings Per Share Reconciliation [Abstract] Remaining estimated useful lives Intangible Asset, Finite-Lived, Useful Life Other generic revenues Sales of Generic Other Revenues [Member] Related to sales of established brand, royalties, and other pharmaceutical services. Exercise Price Award Exercise Price Cash Flows From Investing Activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Related Party Transaction [Axis] Related Party Transaction [Axis] Marketing and distribution rights Marketing and distribution rights Marketing and distribution rights Segment reporting Segment Reporting [Line Items] Net profit generated by the sales Collaborative Arrangement, Owed Net Profit Generated by Sales, Percentage Collaborative Arrangement, Owed Net Profit Generated by Sales, Percentage Maximum net profit generated by sales owed Collaborative Arrangement, Net Profit Generated by Sales, Maximum Owed Collaborative Arrangement, Percentage of Net Profit Generated by Sales, Quarterly Payment Due, Maximum Document Quarterly Report Document Quarterly Report Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Segments [Domain] Segments [Domain] Temporary Equity [Line Items] Temporary Equity [Line Items] Investment, cost Investment Owned, Cost 2021 CREDIT FACILITY 2024 CREDIT AGREEMENT 2.25% CONVERTIBLE SENIOR NOTES Debt Disclosure [Text Block] Mezzanine Equity Series A Convertible Preferred Stock Convertible Preferred Stock Convertible Preferred Stock [Member] Collaborative arrangement, royalty percentage in net sales Collaborative Arrangement, Royalty Percentage to Pay, Net Sales Collaborative Arrangement, Royalty Percentage to Pay, Net Sales Debt instrument, unamortized discount (premium) and debt issuance costs, net Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Deferred debt issuance costs Debt Issuance Costs, Net Supplier Concentration Risk Supplier Concentration Risk [Member] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Equity Component [Domain] Equity Component [Domain] Business combination, divisible revenue Contingent Consideration, Milestone Payment, Denominator Contingent Consideration, Milestone Payment, Denominator PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Measurement Input Type [Domain] Measurement Input Type [Domain] Secured Debt Secured Debt [Member] Total Operating Expenses, net Costs and Expenses Adoption Date Trading Arrangement Adoption Date Minimum conversion period Preferred Stock, Conversion Period, Minimum Preferred Stock, Conversion Period, Minimum Nikhil Lalwani [Member] Nikhil Lalwani Debt instrument, interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Counterparty Name [Domain] Counterparty Name [Domain] Total Stockholders’ Equity Balance Balance Equity, Attributable to Parent Write-off unamortized deferred financing Deferred Debt Issuance Cost, Writeoff Shares awarded upon vesting (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Awarded Per Vesting Period Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Awarded Per Vesting Period APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Assets Assets [Abstract] Title Trading Arrangement, Individual Title Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Accounting Policies [Abstract] Accounting Policies [Abstract] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Three Year Anniversary, Closing Date After Three Year Anniversary, Closing Date [Member] After Three Year Anniversary, Closing Date Insider Trading Policies and Procedures [Line Items] Outstanding/ Unvested at the beginning of the period (in shares) Outstanding/ Unvested at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] PSUs Performance Shares [Member] Alimera Sciences, Inc Alimera Sciences, Inc [Member] Alimera Sciences, Inc Changes in contingent consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Target percentage achieved Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Target Percentage Achieved Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Target Percentage Achieved Selling, general, and administrative Selling, general, and administrative expense Selling, General and Administrative Expense Business Combination [Domain] Business Combination [Domain] Interest expense, net Interest expense, net Interest Income (Expense), Nonoperating Number of shares covered by derivative instrument upon conversion (in shares) Derivative Instrument, Number of Shares Covered by the Derivative Instrument Upon Conversion Derivative Instrument, Number of Shares Covered by the Derivative Instrument Upon Conversion Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Number of operating segments Number of Operating Segments Anti-dilutive shares (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount RSUs Restricted Stock Units (RSUs) [Member] Entity Central Index Key Entity Central Index Key Deferred financing costs Debt Issuance Costs, Noncurrent, Net All Adjustments to Compensation All Adjustments to Compensation [Member] Corporate and Unallocated Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] Business Combination [Axis] Business Combination [Axis] Accrued expenses, accrued compensation, and other Increase Decrease Of Accrued Expenses Compensation And Others The increase (decrease) during the reporting period in liabilities related to accrued compensation, accrued expenses, and others. Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Net Cash and Cash Equivalents Provided by Operating Activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Accounts Receivable Accounts Receivable [Member] 2026 (remainder of the year) Long-Term Debt, Maturity, Remainder of Fiscal Year Interest and dividend income on bank balances Interest Income, Deposits with Financial Institutions Income Statement [Abstract] Income Statement [Abstract] Stockholders’ Equity Equity, Attributable to Parent [Abstract] Document Transition Report Document Transition Report Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Investment, Name [Axis] Investment, Name [Axis] Shares accrue dividends rate Preferred Stock, Dividend Rate, Percentage Operating Expenses Operating Expenses [Abstract] Deferred tax assets, net Deferred Income Tax Assets, Net Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Option Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Capitalized interest related to Construction in Progress Interest Costs Capitalized Adjustment City Area Code City Area Code RSAs Restricted Stock [Member] Accumulated Other Comprehensive Income (Loss), Net of Tax AOCI Attributable to Parent [Member] Document Information [Table] Document Information [Table] All Individuals All Individuals [Member] Non-cash operating lease expense Operating Lease, Right-of-Use Asset, Periodic Reduction Debt instrument, fair value disclosure Debt Instrument, Fair Value Disclosure Series A convertible preferred stock dividends paid Payments of Dividends Beginning balance Ending balance SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Name Forgone Recovery, Individual Name Contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Supplier [Domain] Supplier [Domain] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Statement [Line Items] Statement [Line Items] Total Assets Assets Number of products marketed Number of Products Marketed Without Approved NDAs or ANDAs Number of Products Marketed Without Approved NDAs or ANDAs 2027 Milestone Revenue Payment 2027 Milestone Revenue Payment [Member] 2027 Milestone Payment Call Option Call Option [Member] Preferred Stock, shares issued (in shares) Preferred Stock, Shares Issued Convertible Debt Convertible Debt [Member] Achievement of milestones payment period Achievement of Milestones Payment Period Achievement of Milestones Payment Period Derivative, percentage premium Derivative, Percentage Premium Derivative, Percentage Premium Interest income Interest and Dividend Income, Operating Operating Segments Operating Segments [Member] Summary of allocated expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Debt instrument, legal fees Debt Instrument, Legal Fees Debt Instrument, Legal Fees Customer 3 Customer three [Member] Customer three STOCK-BASED COMPENSATION Share-Based Payment Arrangement [Text Block] Non Employee Director Non Employee Director [Member] n/a Impairment of indefinite lived intangible assets Intangible Asset, Excluding Goodwill, Indefinite-Lived, Impairment Loss PEO PEO [Member] 2028 Long-Term Debt, Maturity, Year Two Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense Royalty payments paid Royalty Payments Paid Royalty Payments Paid Total expense Share-Based Payment Arrangement, Expense NDAs and product rights NDAs and product rights NDAs and product rights Other non-current liabilities Other Liabilities, Noncurrent Goodwill Goodwill Stock-based compensation additional shares authorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Issuance of Common Shares upon Stock Option and ESPP Exercise (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Derivative capped call price per share (in dollars per share) Derivative, Capped Call, Price Per Share Derivative, Capped Call, Price Per Share Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Grate date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Jeanne Thoma [Member] Jeanne Thoma Administrative Fees and Other Rebates Administrative Fees and Other Rebates Administrative Fees and Other Rebates (Accumulated Deficit) Retained Earnings Retained Earnings [Member] Income taxes payable Taxes Payable, Current Revolving Credit Facility Revolving Credit Facility [Member] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Schedule of recurring Level 3 fair value measurements of contingent consideration Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Increase (decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Common Stock, shares outstanding (in shares) Beginning Balance, Common (in shares) Ending Balance, Common (in shares) Common Stock, Shares, Outstanding Award Timing Disclosures [Line Items] Diluted Income Per Share (in dollars per share) Earnings per share, Diluted (in dollars per share) Earnings Per Share, Diluted Entity Current Reporting Status Entity Current Reporting Status Net Cash and Cash Equivalents Used in Financing Activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Total Shareholder Return Amount Total Shareholder Return Amount Amortization of intangible assets Intangible Asset, Finite-Lived, Amortization Expense Brands Sales of Established Brands [Member] Sales of Established Brands Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Intangible Asset, Finite-Lived [Line Items] Definite-Lived Intangible Assets: Intangible Asset, Finite-Lived [Line Items] Research and development Research and Development expense Research and Development Expense 2029 Long-Term Debt, Maturity, Year Three Intangible assets acquired Intangible Asset, Finite-Lived, Acquired Share-Based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Cash Flows From Financing Activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Net Revenues Total net revenues Net revenues Revenue from Contract with Customer, Excluding Assessed Tax Property and equipment, net Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Number of executives and founders Number of Executives and Founders in Employment Agreement Number of Executives and Founders in Employment Agreement Interest income on interest rate swap Other Interest and Dividend Income Unused capacity commitment fee percentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Principal payments on borrowings Repayments of Other Long-Term Debt Product families Number of Product Families Number of Product Families Established brand products Number of Established Brand Products Number of Established Brand Products Performance-Based Restricted Stock Units Performance-Based Restricted Stock Units [Member] Performance-Based Restricted Stock Units INVENTORIES Inventory Disclosure [Text Block] Intangible Asset, Finite-Lived, Class [Axis] Intangible Asset, Finite-Lived, Class [Axis] Issuance of Common Shares upon Stock Option and ESPP Exercise Stock Issued During Period, Value, Stock Options Exercised Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] GOODWILL AND INTANGIBLE ASSETS Intangible Asset and Goodwill [Text Block] Underlying Securities Award Underlying Securities Amount REVENUE RECOGNITION AND RELATED ALLOWANCES Revenue from Contract with Customer [Text Block] Prepaid expenses and other current assets Prepaid Expense, Current Non-current borrowing on debt Long-term Debt, Gross, Non Current Non current portion before unamortized (discount) premium and debt issuance costs, of long-term debt. Increase (decrease) in fair value disclosure Contingent Consideration Classified as Equity, Increase (Decrease) in Fair Value Disclosure Contingent Consideration Classified as Equity, Increase (Decrease) in Fair Value Disclosure Inventories Increase (Decrease) in Inventories Nuray Nuray Chemical Private Limited [Member] Represents the information pertaining to Nuray Chemical Private Limited. Segment Reporting [Table] Segment Reporting [Table] Stock-based compensation shares available Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Schedule of contractual maturity of term loan and DDTL Schedule of Maturities of Long-Term Debt [Table Text Block] Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Table] Title of Individual [Axis] Title and Position [Axis] Sale of Stock [Axis] Sale of Stock [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] All Trading Arrangements All Trading Arrangements [Member] Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Other Performance Measure, Amount Other Performance Measure, Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Operating income Operating Income (Loss) Payment period Collaborative Arrangement, Payment Period Collaborative Arrangement, Payment Period Current Fiscal Year End Date Current Fiscal Year End Date Shares held (in shares) Investment Owned, Balance, Shares Proceeds from issuance of debt Proceeds from Issuance of Debt Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Related Party Transaction [Domain] Related Party Transaction [Domain] Prior to One Year, Closing Date Prior to One Year, Closing Date [Member] Prior to One Year, Closing Date Temporary stock issued, value Temporary Equity, Stock Issued During Period, Value, New Issues Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Entity File Number Entity File Number Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Reclassification Of Assets On Completion Of Project And Launch Of Related Products Reclassification of Assets on Completion of Project and Launch of Related Products [Member] Reclassification Of Assets On Completion Of Project And Launch Of Related Products Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Common Stock, shares issued (in shares) Common Stock, Shares, Issued Measure: Measure [Axis] Finished goods Inventory, Finished Goods, Gross Treasury stock, shares at cost Beginning Balance, Treasury (in shares) Ending Balance, Treasury (in shares) Treasury Stock, Common, Shares Quarterly principal payment, percentage of amount outstanding Debt Instrument, Quarterly Principal Payment, Percentage of Amount Outstanding Debt Instrument, Quarterly Principal Payment, Percentage of Amount Outstanding Accrued royalties Accrued Royalties, Current Customer 2 Customer two [Member] Customer two Cost of sales (excluding depreciation and amortization) Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization Equity Components [Axis] Equity Components [Axis] Accounts receivable, net Increase (Decrease) in Accounts Receivable Related Party Related Party [Member] Product and Service [Domain] Product and Service [Domain] Cash paid for income taxes, net of refunds received Income Tax Paid, after Refund Received Accrued government rebates Accrued Government Rebates Represents amounts accrued for government rebates. Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Entity Interactive Data Current Entity Interactive Data Current Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Stock issued during period, shares, conversion of units (in shares) Stock Issued During Period, Shares, Conversion of Units Entity Small Business Entity Small Business Total comprehensive income, net of tax Comprehensive Income (Loss), Net of Tax, Attributable to Parent Termination Date Trading Arrangement Termination Date Shares purchased to cover employee income taxes (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Payment of 505(b)(2) Earn-Out Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Income taxes Increase (Decrease) in Income Taxes Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Number of consecutive trading days Number of Consecutive Trading Days Number of consecutive trading days. Award expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Other non-current assets Other Assets, Noncurrent Document Type Document Type Accrued expenses and other Accrued Liabilities, Current Fair Value as of Grant Date Award Grant Date Fair Value Contingent consideration classified as equity, fair value disclosure Contingent Consideration Classified as Equity, Fair Value Disclosure Rare Disease and Brands Rare Disease and Brands [Member] Rare Disease and Brands Schedule of Goodwill [Table] Goodwill [Table] Increase (decrease) in temporary equity Increase (Decrease) in Temporary Equity [Roll Forward] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Arrangement Duration Trading Arrangement Duration Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Local Phone Number Local Phone Number Percentage of awards Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Percentage of Awards Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Percentage of Awards Work-in-progress Inventory, Work in Process, Gross Consolidation Items [Axis] Consolidation Items [Axis] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Income Before Income Tax Expense Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Out-License Agreement Out-License Agreement [Member] Out-License Agreement Commitments and Contingencies (Note 12) Commitments and Contingencies Revenues Revenues Gross carrying amount Gross Carrying Amount Intangible Asset, Finite-Lived, before Accumulated Amortization Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Executive Category: Executive Category [Axis] Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Fair value of payments Collaborative Arrangement, Increase (Decrease) in Fair Value of Payments Due Collaborative Arrangement, Increase (Decrease) in Fair Value of Payments Due Counterparty Name [Axis] Counterparty Name [Axis] Liabilities and Stockholders’ Equity Liabilities and Equity [Abstract] Other Commitments [Table] Other Commitments [Table] Intangible Asset, Finite-Lived, Class [Domain] Intangible Asset, Finite-Lived, Class [Domain] Balance Balance Temporary Equity, Carrying Amount, Attributable to Parent Schedule of financial assets and liabilities accounted for at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Inventories Inventory, Net Profit-based milestone payments Profit-based milestone payments [Member] Profit-based milestone payments Award Type [Domain] Award Type [Domain] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount FAIR VALUE Fair Value Disclosures [Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Supplemental disclosure for cash flow information: Supplemental Cash Flow Information [Abstract] Returned goods reserve Increase Decrease In Returned Goods Reserve Amount of increase (decrease) in returned goods reserve. Treasury Stock Purchases for Restricted Stock Vests (in shares) Treasury Stock, Shares, Acquired PEO Name PEO Name Debt instrument, convertible, threshold percentage of stock price trigger Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Upfront payment received Contract with Customer, Liability Payment of Novitium Contingent Consideration Payments on contingent consideration Payment for Contingent Consideration Liability, Financing Activities Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Entity Tax Identification Number Entity Tax Identification Number Unobservable inputs Business Combination, Contingent Consideration, Liability, Measurement Input Total Interest expense Interest Expense, Debt Temporary stock issued (in shares) Temporary Equity, Stock Issued During Period, Shares, New Issues Number of new stock classified as temporary equity issued during the period. Credits/Payments SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Liability Class [Axis] Liability Class [Axis] COMMITMENTS AND CONTINGENCIES Other Commitments [Line Items] Treasury Stock Purchases for Restricted Stock Vests Treasury Stock, Value, Acquired, Cost Method Cash, cash equivalents, and restricted cash, beginning of period Cash, cash equivalents, and restricted cash end of period Total cash, cash equivalents, and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Dividends on Series A Convertible Preferred Stock Preferred Stock Dividends, Income Statement Impact Intangible Asset, Finite-Lived [Table] Intangible Asset, Finite-Lived [Table] Accounts payable Increase (Decrease) in Accounts Payable Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Non-NEOs Non-NEOs [Member] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Debt Instrument [Axis] Debt Instrument [Axis] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Investment, Name [Domain] Investment, Name [Domain] Customer [Domain] Customer [Domain] Schedule of inventories Schedule of Inventory, Current [Table Text Block] 2027 Long-Term Debt, Maturity, Year One Long-Term Debt, Type [Domain] Long-Term Debt, Type [Domain] Schedule of accruals and allowances Schedule Of Valuation And Qualifying Accounts Disclosure [Table Text Block] Schedule Of Valuation And Qualifying Accounts Disclosure Basic Income Per Share (in dollars per share) Earnings per share, Basic (in dollars per share) Earnings Per Share, Basic Measurement Input Type [Axis] Measurement Input Type [Axis] Raw materials Inventory, Raw Materials, Gross Treasury stock purchases for restricted stock vests Payments for Repurchase of Common Stock Total Current Assets Assets, Current Statistical Measurement [Axis] Statistical Measurement [Axis] Insider Trading Arrangements [Line Items] Debt, net Debt, net Long-Term Debt, Excluding Current Maturities Award Type [Axis] Award Type [Axis] Returned Goods Reserve Returned Goods Reserve [Member] Returned Goods Reserve Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Retained earnings (Accumulated deficit) Retained Earnings (Accumulated Deficit) Product and Service [Axis] Product and Service [Axis] Securities held, value Investment in equity securities Equity Securities, FV-NI Debt instrument, convertible, threshold trading days Debt Instrument, Convertible, Threshold Trading Days Contingent consideration fair value adjustment Contingent consideration fair value adjustment Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease) Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Credit Facility - 2021 Credit Facility - 2021 Credit Facility - 2021 Number of reporting units Goodwill, Reporting Unit, Number Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Common Stock Common Stock [Member] Contingent consideration / contingent value rights Contingent consideration / Contingent Value Rights Business Combination, Contingent Consideration, Liability Payment Type [Domain] Payment Type [Domain] Payment Type [Domain] Number of votes per share Common Stock, Number of Votes Per Share Common Stock, Number of Votes Per Share Accrued contingent consideration Business Combination, Contingent Consideration, Change in Contingent Consideration, Asset, Increase (Decrease) Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Cover [Abstract] Cover [Abstract] Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Contractual coupon Contractual coupon Interest Expense, Debt, Excluding Amortization Derivative Contract [Domain] Derivative Contract [Domain] Concentration risk, percentage Concentration Risk, Percentage Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Equity Awards Adjustments Equity Awards Adjustments [Member] Rare Disease total net revenues Total Sales Of Rare Disease Pharmaceutical Products [Member] Total Sales Of Rare Disease Pharmaceutical Products Total Liabilities and Stockholders’ Equity Liabilities and Equity Payment of convertible debt discounts and commissions Debt Instrument, Discounts And Commissions Debt Instrument, Discounts And Commissions Novitium Novitium Information related to the Novitium Pharma LLC. Accrued consideration for acquired product rights and intangible assets Noncash or Part Noncash Acquisition, Consideration Accrued Noncash or Part Noncash Acquisition, Consideration Accrued Additional milestone payment Collaborative Arrangement, Additional Quarterly Payment Collaborative Arrangement, Additional Quarterly Payment Accrued Licensor Payments Accrued Licensor Payments [Member] Accrued Licensor Payments Options Share-Based Payment Arrangement, Option [Member] Maximum potential to vest percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Potential to Vest, Percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Potential to Vest, Percentage Segments [Axis] Segments [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Related Party [Domain] Related and Nonrelated Parties [Domain] Plan Name [Axis] Plan Name [Axis] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Tabular List, Table Tabular List [Table Text Block] Additional paid-in capital Additional Paid in Capital Acquisition of product rights, intangible assets, and other related assets Payments to Acquire Intangible Assets Other (expense) income, net Other (expense)income , net Other Nonoperating Income (Expense) 2022 Plan 2022 Plan Related to the entity's 2022 Stock Incentive Plan for equity-based service awards. One Year Anniversary, Closing Date One Year To Three Years, Closing Date [Member] One Year To Three Years, Closing Date Name Awards Close in Time to MNPI Disclosures, Individual Name Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Term Facility Term Facility Term Facility Debt Instrument, Convertible Terms Of Conversion [Domain] Debt Instrument, Convertible Terms Of Conversion [Domain] Debt Instrument, Convertible Terms Of Conversion Non-current Assets Assets, Noncurrent [Abstract] Earnings allocated to participating securities, Diluted Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Preferred Stock, shares authorized (in shares) Preferred Stock, Shares Authorized One Supplier One supplier [Member] One supplier [Member]. Preferred Stock, $0.0001 par value, 1,666,667 shares authorized; 0 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively Preferred Stock, Value, Issued Adjustment to Compensation: Adjustment to Compensation [Axis] Accruals SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment Class of Stock [Domain] Class of Stock [Domain] Supplier [Axis] Supplier [Axis] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Cash paid for interest, net of amounts capitalized Interest Paid, Excluding Capitalized Interest, Operating Activity Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Earnings allocated to participating securities, Basic Undistributed Earnings (Loss) Allocated to Participating Securities, Basic In Process Research and Development In Process Research and Development [Member] Inventory [Line Items] Inventory [Line Items] Credit Facility [Axis] Credit Facility [Axis] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Trading Price Condition Trading Price Condition [Member] Trading Price Condition ILUVIEN and YUTIQ Sales of ILUVIEN and YUTIQ [Member] Sales of ILUVIEN and YUTIQ Name Measure Name Number of European countries Number Of European Countries In Which Pharmaceuticals Are Approved Number Of European Countries In Which Pharmaceuticals Are Approved INCOME TAXES Income Tax Disclosure [Text Block] Accounts payable Outstanding balances Accounts Payable, Current Pay vs Performance Disclosure [Line Items] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] COMMITMENTS AND CONTINGENCIES Commitments Disclosure [Text Block] Scitus Scitus [Member] Represents the information pertaining to Scitus Pharma Services. Debt Instrument [Line Items] Debt Instrument [Line Items] Exchange per share Common Stock, Exchange Per Share Common Stock, Exchange Per Share Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Additional Paid-in Capital Additional Paid-in Capital [Member] Entity Filer Category Entity Filer Category Intangible Asset, Indefinite-Lived, Class [Axis] Intangible Asset, Indefinite-Lived, Class [Axis] Debt instrument accordion feature increase limit Debt Instrument, Accordion Feature, Increase Limit Debt Instrument, Accordion Feature, Increase Limit Name Trading Arrangement, Individual Name New Term Facility New Term Facility [Member] Senior Secured Term Loan Facility Cash and cash equivalents Cash and Cash Equivalent 2016 Employee Stock Purchase Plan 2016 Employee Stock Purchase Plan 2016 Employee Stock Purchase Plan Net Income Available to Common Shareholders Net income available to common shareholders, Basic Net Income (Loss) Attributable To Common Stockholders, Before Participating Securities Allocation Net Income (Loss) Attributable To Common Stockholders, Before Participating Securities Allocation SS Pharma SS Pharma LLC [Member] Represents the information pertaining to SS Pharma LLC. Contingent consideration, milestone payment, CVRs agreement business days Contingent Consideration, Milestone Payment, Contingent Value Rights Agreement Business Days Contingent Consideration, Milestone Payment, Contingent Value Rights, Distribution Period Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Company Selected Measure Amount Company Selected Measure Amount Accrued royalties Increase (Decrease) in Royalty Payable The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction. Unrealized gain (loss) on investment in equity securities Unrealized (gain) loss on investment in equity securities Equity Securities, FV-NI, Unrealized Gain (Loss) Inventories Inventory, Gross Issuance of Performance Stock Units (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Non-current Liabilities Long-Term Debt, Excluding Current Maturities [Abstract] Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Customer 1 Customer one [Member] Customer one Current Assets Assets, Current [Abstract] Milestone achievement payment Revenue, Remaining Performance Obligation, Variable Consideration Amount Sales Milestones Payment Upon Achievement of Certain Development Non-PEO NEO Non-PEO NEO [Member] Senior Notes Senior Notes [Member] Entity Address, Address Line One Entity Address, Address Line One Chargebacks Chargebacks Chargebacks Income tax expense Expense (benefit) for income taxes Income Tax Expense (Benefit) Debt Instrument, Payment Period [Domain] Debt Instrument, Payment Period [Domain] Debt Instrument, Payment Period [Domain] Adjustments to reconcile net income to net cash and cash equivalents provided by operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Noncash Item [Abstract] Restricted Stock Awards Forfeitures (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Forfeited Temporary Equity, by Class of Stock [Table] Temporary Equity, by Class of Stock [Table] Convertible Notes Payable Convertible Notes Payable [Member] Customer Concentration Risk Customer Concentration Risk [Member] Accruals for Chargebacks, Returns, and Other Allowances SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Award Timing Method Award Timing Method [Text Block] Principles of Consolidation Consolidation, Policy [Policy Text Block] Net Change in Cash, Cash Equivalents, and Restricted Cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Additional contingent consideration Business Combination, Contingent Consideration, Range of Outcomes, Maximum, Amount Market Price Condition Market Price Condition [Member] Market Price Condition Market Performance-Based Restricted Stock Units Market Performance-Based Restricted Stock Units [Member] Market Performance-Based Restricted Stock Units Number of new products Number Of New Products Number Of New Products Conversion price (in dollar per share) Common Stock Conversion Price Represents the conversion price for converting shares of common stock into another class of common stock. Debt Instrument, Payment Period [Axis] Debt Instrument, Payment Period [Axis] Debt Instrument, Payment Period Payments for capped call transactions Payments For Capped Call Transactions Payments For Capped Call Transactions Net Income Net Income Net Income Net Income (Loss) Attributable to Parent Estimate number of shares percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Estimate Number of Shares, Percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Estimate Number of Shares, Percentage Long-Term Debt, Type [Axis] Long-Term Debt, Type [Axis] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Probability-weighted discounted cash flow Valuation Technique, Discounted Cash Flow [Member] Location, Statement of Financial Position, Balance [Axis] Location, Statement of Financial Position, Balance [Axis] Statement [Table] Statement [Table] Restatement Determination Date: Restatement Determination Date [Axis] Net income available to common shareholders, Diluted Undistributed Earnings, Diluted Proceeds from stock option exercises and ESPP purchases Proceeds from Stock Options Exercised Basic Undistributed Earnings (Loss) Available to Common Shareholders, Basic [Abstract] Debt instrument, convertible, threshold consecutive trading days Debt Instrument, Convertible, Threshold Consecutive Trading Days Number of complaints filed Loss Contingency, New Claims Filed, Number Payment Type [Axis] Payment Type [Axis] Payment Type Supplemental non-cash investing and financing activities: Other Noncash Investing and Financing Items [Abstract] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Diluted Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]